Nicholas J. Viney

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Sotirios Tsimikas, Ewa Karwatowska‐Prokopczuk, Ioanna Gouni‐Berthold et al. · New England Journal of Medicine · 2020 · 1K citations · Full text

Life Sciences, Genetics, Pharmacotherapy +17

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Nicholas J. Viney, Julian C. van Capelleveen, Richard S. Geary et al. · The Lancet · 2016 · 748 citations

Medicine, Pharmacology, Clinical Pharmacology +6

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

Daniel Gaudet, Veronica Alexander, Brenda F. Baker et al. · New England Journal of Medicine · 2015 · 528 citations · Full text

Medicine, Biochemistry, Pharmacology +14

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

Sotirios Tsimikas, Nicholas J. Viney, Steven G. Hughes et al. · The Lancet · 2015 · 464 citations

Medicine, Molecular Medicine, Pharmacology +7

Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy

Teresa Coelho, Wilson Marques, Noel R. Dasgupta et al. · JAMA · 2023 · 207 citations · Full text

Medicine, Neurology, Pharmacotherapy +16